A comprehensive analysis of the major specificities of anti-human T lymphocyte porcine immunoglobulin (p-ATG).

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-10-15 DOI:10.1007/s00277-024-06028-9

Haoyong Zou, Wenqu Yin, Peng Geng, Li Lin, Xilin Nie, Zui Tao, Gang Chen, Bin Chen, Hao Feng, Kuanhong Xu, Zhi Zhang

{"title":"A comprehensive analysis of the major specificities of anti-human T lymphocyte porcine immunoglobulin (p-ATG).","authors":"Haoyong Zou, Wenqu Yin, Peng Geng, Li Lin, Xilin Nie, Zui Tao, Gang Chen, Bin Chen, Hao Feng, Kuanhong Xu, Zhi Zhang","doi":"10.1007/s00277-024-06028-9","DOIUrl":null,"url":null,"abstract":"Background: Anti-human T lymphocyte porcine immunoglobulin (p-ATG) is a potent immunosuppressive agent derived from porcine sources used in various immunotherapy applications. It is compared with similar products derived from other species, such as rabbit anti-thymocyte globulin (r-ATG) and ATG-Fresenius (ATG-F), which have distinct biological and therapeutic properties. This study aims to elucidate the mechanisms of action and comparative efficacy of p-ATG in relation to r-ATG and ATG-F through a comprehensive in vitro analysis.Methods: A comparative analysis of p-ATG, r-ATG and ATG-F was performed, focusing on E rosette inhibitory potency, lymphocyte toxic potency, blocking activities of 24 CD molecules, and flow quantitative potency. Flow cytometric analysis was used to quantify these characteristics and assess the potency of the immunoglobulins.Results: p-ATG exhibited lower E rosette inhibitory and lymphocyte toxic potencies compared to r-ATG but was significantly more potent than ATG-F at equivalent concentrations. At protein concentrations above 12.5 µg/mL, p-ATG showed slightly lower potency than r-ATG and much higher potency than ATG-F in flow cytometry assays. Both p-ATG and r-ATG exhibited similar killing effects on lymphocytes within the peripheral blood mononuclear cells (PBMCs), including CD3 + T cells, with a dose-dependent response. Notably, p-ATG displayed more pronounced blocking activities against CD8, CD99, and TCR α/β compared to r-ATG.Conclusion: p-ATG offers certain advantages over r-ATG and ATG-F, particularly in its ability to inhibit specific CD molecules and its overall potency in immunosuppressive assays, providing valuable insights for assisting clinical decision-making regarding the selection of ATG types based on patient-specific needs and treatment objectives.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-024-06028-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anti-human T lymphocyte porcine immunoglobulin (p-ATG) is a potent immunosuppressive agent derived from porcine sources used in various immunotherapy applications. It is compared with similar products derived from other species, such as rabbit anti-thymocyte globulin (r-ATG) and ATG-Fresenius (ATG-F), which have distinct biological and therapeutic properties. This study aims to elucidate the mechanisms of action and comparative efficacy of p-ATG in relation to r-ATG and ATG-F through a comprehensive in vitro analysis.

Methods: A comparative analysis of p-ATG, r-ATG and ATG-F was performed, focusing on E rosette inhibitory potency, lymphocyte toxic potency, blocking activities of 24 CD molecules, and flow quantitative potency. Flow cytometric analysis was used to quantify these characteristics and assess the potency of the immunoglobulins.

Results: p-ATG exhibited lower E rosette inhibitory and lymphocyte toxic potencies compared to r-ATG but was significantly more potent than ATG-F at equivalent concentrations. At protein concentrations above 12.5 µg/mL, p-ATG showed slightly lower potency than r-ATG and much higher potency than ATG-F in flow cytometry assays. Both p-ATG and r-ATG exhibited similar killing effects on lymphocytes within the peripheral blood mononuclear cells (PBMCs), including CD3 + T cells, with a dose-dependent response. Notably, p-ATG displayed more pronounced blocking activities against CD8, CD99, and TCR α/β compared to r-ATG.

Conclusion: p-ATG offers certain advantages over r-ATG and ATG-F, particularly in its ability to inhibit specific CD molecules and its overall potency in immunosuppressive assays, providing valuable insights for assisting clinical decision-making regarding the selection of ATG types based on patient-specific needs and treatment objectives.

查看原文本刊更多论文

抗人 T 淋巴细胞猪免疫球蛋白（p-ATG）主要特异性的综合分析。

背景：猪抗人类 T 淋巴细胞免疫球蛋白（p-ATG）是一种从猪来源提取的强效免疫抑制剂，可用于各种免疫疗法。它与其他物种的同类产品（如兔抗胸腺细胞球蛋白（r-ATG）和 ATG-Fresenius（ATG-F））相比，具有不同的生物和治疗特性。本研究旨在通过全面的体外分析，阐明 p-ATG 与 r-ATG 和 ATG-F 的作用机制和疗效比较：方法：对p-ATG、r-ATG和ATG-F进行了比较分析，重点是E roset抑制效力、淋巴细胞毒性效力、24种CD分子的阻断活性和流式定量效力。结果：与 r-ATG 相比，p-ATG 的 E roset 抑制效力和淋巴细胞毒性效力较低，但在同等浓度下，p-ATG 的效力明显高于 ATG-F。在蛋白质浓度超过 12.5 µg/mL 时，p-ATG 的效力略低于 r-ATG，而在流式细胞仪检测中，p-ATG 的效力则远高于 ATG-F。p-ATG 和 r-ATG 对外周血单核细胞（PBMCs）中的淋巴细胞（包括 CD3 + T 细胞）具有相似的杀伤作用，且呈剂量依赖性反应。结论：与r-ATG和ATG-F相比，p-ATG具有一定的优势，尤其是在抑制特定CD分子的能力和免疫抑制试验中的整体效力方面，为临床根据患者的特定需求和治疗目标选择ATG类型提供了有价值的帮助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.